Suvretta Capital Management
Avalyn Pharma Raises $100M to Advance Inhaled Lung Disease Drugs
Avalyn Pharma; $100 million Series D; inhaled lung disease medications; pulmonary fibrosis; AP01; AP02; pirfenidone; nintedanib; clinical trials; drug safety; side effects; Suvretta Capital Management; SR One; Novo Holdings